Afya Limited (NASDAQ:AFYA – Get Free Report) has received an average recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $18.75.
A number of research analysts have commented on AFYA shares. Weiss Ratings restated a “hold (c)” rating on shares of Afya in a research note on Wednesday, October 8th. UBS Group raised Afya from a “neutral” rating to a “buy” rating and lowered their price target for the company from $19.50 to $19.00 in a research note on Monday, September 8th. Wall Street Zen lowered shares of Afya from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, JPMorgan Chase & Co. upgraded shares of Afya from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $23.50 to $24.50 in a research note on Monday, September 8th.
Get Our Latest Research Report on AFYA
Hedge Funds Weigh In On Afya
Afya Trading Down 0.7%
Shares of NASDAQ:AFYA opened at $14.70 on Wednesday. Afya has a 12-month low of $13.47 and a 12-month high of $19.90. The company has a quick ratio of 0.98, a current ratio of 0.98 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $1.38 billion, a P/E ratio of 10.58, a price-to-earnings-growth ratio of 0.52 and a beta of 0.52. The firm has a fifty day moving average of $14.66 and a two-hundred day moving average of $15.37.
About Afya
Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.
At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.
Recommended Stories
- Five stocks we like better than Afya
- The boring AI play that could pay up to $4,290 monthly
- Put $1,000 into this stock by Jan 1 [Not NVDA]
- Trump’s “real estate deal for America” explained
- A month before the crash
- Trump Did WHAT??
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.
